Načítá se...
Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research
Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of...
Uloženo v:
| Vydáno v: | Cureus |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Cureus
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5910011/ https://ncbi.nlm.nih.gov/pubmed/29692957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.2130 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|